Geron Stock (NASDAQ:GERN)
Previous Close
$1.66
52W Range
$1.04 - $2.01
50D Avg
$1.51
200D Avg
$1.37
Market Cap
$1.02B
Avg Vol (3M)
$13.80M
Beta
0.62
Div Yield
-
GERN Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
GERN Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
Annual
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| Total Gross To Net Adjustments | $-39.49M | $-12.92M |
| Sales Returns And Allowance | $-3.85M | $-225.00K |
| Revenues Before Adjustments | $223.11M | $89.42M |
| Product | $183.62M | $76.50M |
| Government Rebates | $-2.60M | $-926.00K |
| Chargebacks | $-25.52M | - |
| Chargeback And Distributor Service Fees | - | $-11.77M |
Latest
Fiscal year ends in Dec 25 | Currency in USD